Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|December 27, 2017
Universal Flu Vaccine: Is It Possible?
Author(s)Contagion® Editorial Staff
William Schaffner, MD, discusses efforts to develop a universal flu vaccine.
Advertisement
William Schaffner, MD, medical director of the National Foundation for Infectious Diseases, discusses efforts to develop a universal flu vaccine.
Interview Transcript (modified slightly for readability):
“Scientists in universities, in the federal government, in the vaccine industry are all working to create better influenza vaccines. For example, we now have two vaccines formulated for people aged 65 and older; they work better. And, some of my friends are working in the laboratory to create a universal flu vaccine, one that would cover a whole variety of strains, which, perhaps, we might only have to get every five or ten years.
But that’s not the vaccine we have today. The vaccine we have today has to be given each and every year. So, let’s use the one that we have today to our best advantage, while we have a look to the future and high hopes down the road.”
Advertisement
Related to this article
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
The death was reported in Jefferson County where the coroner released a statement announcing it was in an unvaccinated woman.
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
Advertisement
Advertisement
Trending on Contagion Live
1
New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework
2
On World Rabies Day, When to Seek Treatment, Clinical Considerations for Post Exposure Prophylaxis
3
Further Insights, Treatment Considerations Around the PETERPEN Study
4
Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization
5